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Abstract 
 
The DNA damage response (DDR) is essential for maintaining the genomic integrity of the cell and its 
disruption is one of the ‘Hallmarks of Cancer’. Classically, defects in the DDR have been exploited 
therapeutically in the treatment of cancer by radiation therapies or by genotoxic chemotherapies.  More 
recently, protein components of the DDR systems are being identified as promising avenues for 
targeted cancer therapeutics.  Here we present an in-depth analysis of the function, disease role and 
therapeutic potential of ~450 expert-curated human DDR genes. We discuss the current state of DDR 
drugs both FDA approved or under clinical investigation. We examine large-scale genomic and 
expression data in 15 cancers to identify deregulated components of the DDR in these tumours, and we 
apply systematic computational analysis to identify DDR proteins amenable to modulation by small 
molecules, highlighting potential novel therapeutic targets. 
  3 
The DNA Damage Response (DDR) evolved in response to the exposure of the genome to exogenous 
and endogenous genotoxins.  Unless repaired in an error-free process, DNA damage can result in 
mutations and altered cellular behavior.  Consequently, cells deploy a diverse repertoire of mechanisms 
to maintain genetic integrity1 (see TABLE 1).  These mechanisms involve the DNA repair processes 
themselves, the systems that regulate and organize them, and the systems that integrate DNA damage 
repair with the cell cycle2.  
Disruption of the DDR is observed in many cancers3-5, and underlies the genomic instability that 
accompanies tumourigenesis and progression.  However, in the majority of cases, the specific 
underlying defects are poorly characterised6, 7. Conversely, there are well-described cancers where 
disruption of a DDR mechanism is directly causal. Examples include hereditary non-polyposis 
colorectal cancer (HNPCC or Lynch Syndrome), associated with loss-of-function mutations in mismatch 
repair (MMR) genes – most commonly MSH2 and MLH18.  Current theories propose that DDR defects 
in tumour development and progression are positively selected by the need to tolerate oncogene-
induced replication stress and/or by the adaptive advantage provided by an increased mutation rate 
during tumour evolution.  
While DDR defects are causative and permissive of disease, they open a weakness that can be 
exploited therapeutically9-12.  Genotoxic drugs that cause DNA damage exceeding the repair capacity of 
DDR systems, have been the mainstay of cancer chemotherapy for over 30 years.  These include 
drugs that alkylate bases (eg temozolomide)13, covalently crosslinks strands (eg cisplatin)14, or cleave 
the sugar-phosphate backbone (eg bleomycin)15.   There are also drugs for approximately ten protein 
targets that modulate DDR indirectly (see Supplementary information S1 (table) and Fig 1), albeit 
mostly through genototoxic effects.  These include inhibitors of proteins involved in DNA synthesis, 
(e.g. DNA polymerases), proteins regulating epigenetic control (e.g. DNMT1) and proteins with an 
indirect role in DNA replication (e.g. topoisomerases). 
In addition to these licensed drugs, there are a number of compounds currently under clinical 
evaluation that target DDR pathways directly. These targets include the protein kinases involved in cell 
cycle DNA checkpoint for DNA damage and/or replicative stress (eg CHEK1, WEE1), and individual 
enzymes involved in base excision repair (BER; APEX1), direct repair (MGMT), non-homologous DNA 
double strand break repair (NHEJ; PRKDC / DNA-PK) and telomere maintenance (TM; TERT). 
The initial rationale for development of DDR enzyme-targeted drugs focused on their use as 
potentiators, inhibiting repair of damage caused by radiotherapy and/or conventional genotoxins
11.  
However, this approach has been extended to stand-alone use, targeting DNA repair pathways critical 
to tumour survival by exploiting synthetic sensitivity/lethality16 (SSL).  SSL arises when a combination of 
loss-of-function in two or more genes leads to cell death, while loss-of-function in only one of them does 
not.  The therapeutic aim is to exploit genetic defects essential to a tumour’s survival by combining the 
defect in an affected pathway with a pharmacologically induced defect in a compensating pathway17.  
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The best example to date is the pharmaceutical inhibition of PARP1 9 a key enzyme in SSBR, which is 
SSL with genetic defects in the BRCA1, BRCA2 or PALB2 homologous recombination (HR) proteins 
observed in hereditary breast, ovarian, pancreatic, and prostate cancers. The furthest progressed 
PARP inhibitor, olaparib (AZD-2281), recently entered large scale Phase III evaluation for ovarian 
cancer in patients with BRCA mutations.  
To help identify new therapeutic opportunities we have assembled a comprehensive dataset of DDR 
proteins, classified by the molecular processes in which they occur. We have assessed them 
systematically using a range of bioinformatics and chemogenomic approaches to define their 
involvement in oncogenesis, and to identify their suitability for functional inhibition by small molecules. 
Unlike the protein kinase signalling pathways that have been the focus of much anti-cancer drug 
development in the past 
18, DDR proteins have diverse structures and functions, and major efforts in 
target identification and validation are needed before they can be fully exploited. Moreover, as many 
cancer-associated mutations of DDR proteins are loss-of-function rather than activating as in kinases19, 
20, a systems biology approach is needed to identify the best targets, which often will not be the 
mutated protein itself.  The ultimate aim of this study is to identify ‘druggable’ points of intervention 
within the DDR network, on which drug discovery might be effectively focused. 
 
Assignment of proteins to DNA Damage Response Processes 
We compiled a dataset of 449 genes encoding proteins integral to the DDR (Supplementary information 
S2 and S3 (table)) utilising several strategies.  Firstly a panel of experts in the core DDR pathways 
defined the key genes within their pathway(s) of expertise.  This list was expanded by entries in 
pathway databases (eg KEGG21, reactome22) annotated as belonging to DDR processes.  Proteins 
functionally or physically interacting with this set of gene products were identified using STRING23 and 
their candidacy for inclusion assessed by confirmative Gene Ontology terms24 and by consulting the 
literature. The expanded list was re-reviewed by the experts and omissions and mis-inclusions rectified. 
The complete list includes genes involved in ‘core’ DDR activities, such as BER, MMR, HR etc. 
However, this core machinery does not work in isolation, but is integrated with complementary 
processes essential to overall genome maintenance. Consequently we have also included proteins not 
directly involved in DNA damage sensing or repair, but required for regulating or facilitating DDR, and 
which may therefore provide viable druggable intervention points for modulating DDR.  TABLE 1 
summarises the major processes included, with the number of genes involved in each. 
Core DDR Pathways. These are a set of functionally distinct, intertwined pathways, defined historically 
by the biochemical mechanism they utilise to achieve repair.  Each typically include a series of ordered 
processes comprising a) the detection of DNA damage, b) recruitment of proteins to the site of the 
damage, and c) repair of the physical lesion.  These core pathways include those that directly reverse 
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DNA damage, excise mismatched and chemically modified bases and nucleotides, and repair single 
strand breaks, double strand breaks and intra- and inter-stand crosslinks. 
The core also includes tolerance mechanisms that confer viability in the presence of unrepaired DNA 
damage. The best described of these, translesion synthesis (TLS), consists of a set of specialised DNA 
polymerases and regulatory proteins that allow replication across template lesions that would otherwise 
block progress of replicative DNA polymerases. In the absence of TLS, unrepaired lesions cause 
replication fork collapse, generating single-ended double-strand breaks that promote illegitimate 
homologous recombination and aneuploidy. 
Processes facilitating DDR. These include chromatin remodelling, which facilitates access to DNA 
damage; and chromosome cohesion and alignment, which ensure legitimate homologous 
recombination between sister chromatids. Telomere maintenance acts as a barrier to genomic 
instability by preventing inappropriate involvement of chromosome ends in recombination events.   
Repair of ‘architectural’ damage such as double-strand breaks (DSB)s or strand crosslinks, also 
requires the integration of cell cycle control via DNA damage checkpoint signalling, to allow time for 
repair and to prevent cells entering mitosis with substantial unrepaired damage. Consequently 
checkpoint factor (CPF) proteins are included in the dataset.  Similarly many proteins involved in the 
ubiquitination response (UR) are included due to their roles in mediating DDR complex assembly and 
disassembly. Topoisomerases and the enzymes that release stalled topoisomerases are also included, 
as their modulation impacts the DDR response. A general category encompasses those proteins 
strongly implicated in effective DDR, but not identified as components of one of the above processes. 
We devised a hierarchical classification that assigns proteins to the pathways, processes and 
complexes to which they contribute (Supplementary information S3 (table)). For instance, several 
proteins involved in DSBR could be assigned to the Fanconi anaemia pathway (FA), HR or Non-
homologous End-joining (NHEJ) pathways.  At the next level proteins were assigned to the functional 
complexes in which they participate;  i.e. FA proteins could be assigned to the FA core complex or the 
Bloom’s syndrome complex, amongst others. Proteins were not limited to a single assignment and if 
involved in more than one process were assigned to each. 
 
DDR protein interaction network 
Although many DDR processes can be considered as linear pathways, the proteins involved often 
participate in multiple complexes and may have different roles in different processes. Furthermore 
pathway definitions are incomplete as new genes (eg
25), and new roles for existing genes are still being 
elucidated (eg26). We have therefore sought to develop a systems biology representation of the DDR 
which provides a more holistic view of the integration and inter-dependencies of DDR processes.   
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Using experimentally defined protein-protein interactions from the STRING23 database we were able to 
construct an interaction network, annotated by pathway, that encapsulates the cellular connectivity of 
409 of the DDR proteins in our list (Fig 2). While the majority of DDR proteins lie within a single 
pathway (86%), over half (56%) interact with proteins involved in other DDR pathways.  This high level 
of interconnectedness presents potential challenges for pharmacological intervention, as inhibition of a 
target aimed at disrupting one DDR mechanism may affect several systems and generate unanticipated 
toxicities. However in other circumstances affecting multiple systems may be advantageous. A systems 
biology view of the interconnectedness of DDR pathways will be critical to understanding the cellular 
response to DDR-directed drugs and will help elucidate mechanisms of resistance that are not yet 
clearly understood. 
 
Functional Characterisation of DDR proteins 
Discovery of small molecule modulators of new target classes is particularly challenging and it is much 
easier to identify hits for protein classes that have already been successfully drugged. We therefore 
compared the classes of proteins comprising the DDR with those already successfully targeted in 
cancer generally, to identify the most tractable opportunities. 
We classified the DDR proteins into major functional classes (Fig 3a). Enzymes constituted 40%; 
scaffold proteins (or non-catalytic components of a multi-protein catalytic complex) 24%; enzyme 
regulators (6%) and transcription factors and regulators (9%).  The major enzymatic classes were 
helicases (7%), ubiquitin ligases (5%), nucleases (5%) and polymerases (5%), with protein kinases 
comprising just 4%. The fraction of enzymes in the DDR (40%) is lower than in approved drug targets 
across all therapeutic areas (~50%)
27 and substantially lower than amongst general cancer targets, 
(~60%)28; but enriched in comparison with cancer-causing genes29 that more typically constitute 25%-
30% enzymes. The distribution of enzymatic classes in DDR differs markedly from current cancer 
targets. While over a third (38%) of cancer targets with approved drugs are protein kinases, these 
comprise a minor fraction of the DDR, whereas helicases, for which there are no currently licensed 
drugs, comprise 7% of the DDR. 
Consistent with their biological role, the vast majority (97%) of DDR proteins display strong nuclear 
localisation, in contrast to only 10% of the current portfolio of current cancer targets. While small 
molecules traverse the nuclear pores without difficulty, different chemotypes may be needed if high 
nuclear concentrations are required for effective inhibition of DDR. In a similar vein, the large amount of 
DNA in the nucleus and the consequently high concentration of off-target binding sites (intercalation / 
minor groove) particularly for basic and/or planar molecules, may present unanticipated challenges for 
drug availability. 
 
Disease association of DDR proteins. 
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DDR processes maintain genomic integrity and regulated cellular function, so that defects in DDR 
genes are frequently associated with diseases, including cancer (Supplementary information S4 
(table)).  Of the ~450 DDR genes in this analysis, defects in more than a quarter are disease 
associated - these are not restricted to specific systems, but are widely distributed throughput the DDR.  
Germline defects in 57 genes are linked to inherited cancer predisposition or cancer–related 
syndromes, and 38 to inherited syndromes unrelated to cancer.  Several DDR genes associated with 
familial cancer predisposition syndromes due to inactivating germline mutations, (e.g. TP53, MSH6, 
MSH2, MLH1, ATM, SMARCB1 and CDKN2A) are also frequently somatically mutated in a variety of 
cancers, emphasising their roles as tumour suppressors, and highlighting the DDR pathways in which 
they participate as critical for marinating genomic stability. However other tumour suppressors such as 
BRCA1 and BRCA2, which have strong germline associations with familial cancers, are only rarely 
found to be mutated in somatic cancers, although they are more frequently epigenetically silenced
30.  In 
some cases disease presentation depends on whether germline mutations are heterozygous or 
homozygous. Thus, heterozygous loss-of-function mutations in BRCA2 or PALB2 predispose to early-
onset breast31, ovarian32, prostate33, 34 and pancreatic cancers35 while homozygous mutations manifest 
as Fanconi anaemia36. 
Mostly, DDR defects implicated in cancer predisposition, genetic diseases and somatic cancers arise 
from mutations causing a ‘loss of function’ of the protein product 19, 37.  Further analysis of somatic 
mutation patterns in these genes4, 38 using the 20:20 rule3, 39 predicts a five fold enrichment in tumour 
suppressors over oncogenes (see Supplementary information S5 (table)). Identifying potential 
druggable targets within the DDR is challenging as we predict that a majority of DDR genes are likely to 
act as tumour suppressors, and not as the activated gene products more conventionally targeted in 
cancer drug discovery. Rarely it may be feasible to directly reactivate a mutationally inactivated tumour 
suppressor. Post-translational reactivation (rather than reactivation of transcription of an epigenetically 
silenced tumour suppressor) requires that the inactivating mutation does not ablate the protein product, 
but generates an altered form whose biochemical function can be restored by binding of a stabilising or 
modifying ligand. This approach is primarily being explored in the context of destabilising mutations of 
TP53 (reviewed in 
40), where restoration of TP53 function could trigger apopotosis of genetically 
damaged tumour cells.  
The alternative strategy which we explore in detail below is the identification of other gene products 
within and without the DDR, whose loss-of-function is not itself lethal to a cell, but becomes so in the 
presence of a cancer-associated mutation in a DDR component. 
 
Systematic evidence for DDR deregulation from large-scale patient data 
As inactivation of DDR pathways typically leads to increased genomic instability, a hallmark of 
carcinogenesis and cancer progression, we looked at the frequency with which these genes are 
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mutated, significantly over and under-expressed or have copy number alterations, in a range of cancers 
using data from The Cancer Genome Atlas (TCGA)4, 41, 42.  Our analysis shows that 95% of DDR genes 
catalogued here had coding region mutations  (i.e. missense, frame-shift, indel or nonsense) within the 
fifteen cancers studied. The level of mutation observed reflects the genetic instability of the individual 
tumour and not all of the mutations will contribute to the cancer phenotype. On average each patient 
accrued 3.12 coding mutations in DDR genes, but the averages differed significantly between cancer 
type.  
Diseases with the most DDR mutations were those associated with known mutator phenotypes. 
Colorectal cancers, which commonly have MMR defects, had the highest frequency of DDR gene 
mutations with an average of 11.44 DDR mutations per patient.  Similarly uterine corpus endometroid 
carcinoma
43 had a very high level of mutations amongst DDR genes (7.69 mutations per patient). Many 
of the endometrial tumours had mutations of the proofreading DNA polymerases POLE or POLD1 that 
reduce the fidelity of DNA replication, and also had a high level of MMR mutations.  The lung cancers 
analysed (squamous cell and adenocarcinoma) also exhibited a high number of DDR mutations (3.93 
mutations per patient) reflecting the large proportion (>75%) of tobacco smokers in the cohorts 
sequenced. Smokers often display a high level of C-A transversions due to the mutagenic effects of 
tobacco smoke 
44 often accumulated before the onset of disease.  Those with the least DDR gene 
mutations, include acute myeloid leukaemia (AML) and glioblastoma multiforme45, 46, averaging less 
than one DDR gene mutation (0.70 and 0.97 mutations/patient respectively). The mutational 
frequencies reflect those observed in the complete genome and are characteristic of individual disease, 
however the majority of the cancers analysed here are enriched for DDR protein coding mutations (see 
Fig 3c and Supplementary information S6(fig)) suggesting that DDR disruption is important to these 
cancers.  AML, ovarian cancer and glioblastomas are the most enriched in DDR coding mutations, 
although the total number of mutations may be low. Those not exhibiting enrichment were cervical 
squamous cell carcinoma, which usually has a viral etiology, with viral proteins disabling tumour 
suppressors, and the lung cancers, where genome–wide mutations accumulate due to carcinogen 
exposure prior to disease onset. 
A fairly large proportion (60%) of DDR genes were over-expressed in at least 10% of disease specific 
patient samples, however far fewer (5%) were significantly under-expressed.  There was also a 3-fold 
increase in the number of genes expressed (2.7%) compared to non-DDR genes (0.74%),  Similarly, in 
at least 10% of disease specific patient samples, 4% show a copy number gain whereas 1% show 
genomic loss.  However there was no enrichment on the proportions of genes exhibiting copy number 
alterations (Supplementary information 6 (table)). Taken together, the data suggests that the genomic 
instability resulting from mutational damage and functional impairment in one part of the DDR, may 
promote the up-regulation of compensatory pathways in other parts of the global DDR system.   
Using these data we identified the genes disrupted (defined as mutated, or significantly altered in copy 
number or expression level), within each DDR process (see Supplementary information S7(table)) for 
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the fifteen cancer types studied, to generate DDR pathway-based disruption signatures for each cancer 
(Fig. 4). A gene was considered disrupted if the anomaly was observed in at least 2 patients.  
We found every DDR process was functionally impaired to a greater or lesser extent in one or more 
cancer type. However, the types of DDR process impaired, and how often these defects are observed 
in patient samples, differed amongst cancer types. Some cancers are restricted in the processes 
disrupted, whereas others are surprisingly heterogeneous with different pathways and combinations of 
pathways varying in different patients. In glioblastoma multiforme, mutations concentrate in P53 
pathway genes, and cell-cycle checkpoint factors, with a far lower frequency observed in other DDR 
processes.  In AML they concentrate in chromatin segregation and those classified in ODSBR, which 
includes NPM1 – a major prognostic biomarker in AML, which has been implicated in DSB repair as 
well as a range of other nuclear functions 
47.  Conversely, colon adenocarcinoma48 displays mutations 
in all DDR processes.   
These signatures also define patterns of disruption. For example, although colorectal cancers are often 
associated with MMR defects, a similar proportion have HR defects, and although exhibiting far fewer 
DDR gene mutations, the relative proportions of the DDR mutations in pathways in lung and bladder 
cancers mirror those found in colon cancer.  This suggests that stratification of DDR disruption 
subtypes in these diseases could ultimately lead to more effective targeted therapy, with different 
patterns of disruption being treated with different therapeutic regimes.  
 
Synthetic Lethalities within the DDR 
Apart from attempts to stabilise mutant TP5349, direct targeting of the defective products of mutated 
DDR genes is unlikely to have therapeutic benefit.  Instead, therapeutic interventions must be targeted 
towards other proteins whose function is largely dispensable in normal cells, but becomes essential (or 
at least important) in the genetic context of the DDR mutation – providing synthetic lethality (SSL) or 
sensitisation. The challenge then for effectively exploiting the plethora of DDR mutations in cancers, is 
the identification of SSL counterparts of disease-affected DDR proteins/pathways, and the development 
of a non-toxic small molecule modulator of that counterpart protein or pathway. 
The exquisite sensitivity to pharmacological disruption of SSBR via inhibition of PARP-1 in HR-deficient 
tumours is the best established example of SSL
50. While this may be an extreme example resulting 
from the inherent background occurrence of single-strand breaks in all cells, experience in dissecting 
DDR pathway interactions in model organisms and cell systems suggests that there will be many 
opportunities to exploit SSL in tumours with diverse genetic profiles. Other reported SSL examples 
include, siRNA knock-down of POLB in an MSH2 deficient background, and inhibition of POLG in an 
MLH1 deficient background51. As the MLH1 and MSH2 mismatch repair proteins are mutationally 
inactivated in a high proportion of bowel cancers, inhibitors of these DNA polymerases could have far 
more clinical impact than PARP-1 inhibitors, which work in BRCA1, BRCA2 and PALB2 defective 
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backgrounds largely restricted to relatively rare familial breast, ovarian, prostate and pancreatic 
cancers. Opportunities for SSL may also occur between DDR systems and other parts of the cells 
regulatory apparatus, as well as between different DDR systems.  
Yeast genetic interaction screens have been used to predict synthetic lethal partners of human cancer 
genes52: To identify putative DDR SSL pathway interdependencies in humans we identified yeast 
negative genetic interactions using BioGrid53 and mapped onto them the corresponding human 
orthologues.   Figure 5a shows the predicted SSLs of human DDR orthologues, grouped by pathway 
and the predictions are detailed in Supplementary information S8(table).  These indicate multiple SSL 
interdependencies between the major pathways, which have the potential to be exploited 
therapeutically.  However there are limitations to this method in that only 54% of human DDR genes 
have yeast orthologues and genetic interaction screens have erratic reproducibility.  
As expected from the severe consequences of unrepaired DSBs, HR and NHEJ pathways show a high 
level of SSL with many other pathways. The major cluster of SSL relationships occurs between HR and 
NER. Given the role of NER in the removal of bulky adducts and gross distortions, this strong SSL 
effect likely results from impairment of HR-dependent rescue of replication forks collapsed at a blocked 
template. The biochemistry underlying some SSL relationships is less clear. For example LOF mutation 
of MSH2 shows an SSL relationship in yeast with LOF of the HR exonuclease MRE11, and the 
absence of functional MSH2 affects the activity and localisation of MRE11 in mammalian cells via 
mechanisms that appears quite distinct from the canonical function of MSH2 in mismatch repair
54. The 
complexity of the SSL relationships again highlights the poorly understood interconnectedness of the 
canonical pathways and the intricate relationships between their component proteins.   
The SSL data identify several opportunities for exploiting existing therapies in novel genetic 
backgrounds (Fig 5b). The TOP1 inhibiters irinotican and topotecan are used in first line treatment of 
colorectal cancers in combination with 5-flurouracil, and as second line treatment for ovary, cervix and 
small cell lung cancers in combination with cisplatin. In yeast, the homologues of TOP1 and PBRM1 
show SSL.  PBRM1 is mutated in 24% of kidney and 3.5% of all cancers. If this SSL is conserved in 
humans, a TOP1 inhibitor may be effective in these cancers when PBRM1 is defective. Similarly 
CHEK2 inhibitors are predicted to have utility in a MSH2 impaired background, observed in 8% of 
colorectal and 1% of all cancers.  The data also reveals some new potentially druggable targets (see 
below) for these genetic backgrounds including MRE11A (MSH2 deficient), and ASF1B  (PBRM1 
deficient).   
There are a wealth of other druggable targets such as FEN1, WRN and RAD52 whose yeast 
homologues are SSL with homologues of a range of less frequently mutated cancer genes (see 
Supplementary information 8(figure) and 9(table)). Many of the observed SSL relationships can be 
rationalised biochemically due to the high degree of interconnectedness of DDR pathways (Fig 2), 
although few of them would be predicted ab initio.  
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Expanding druggable opportunities in DDR 
To establish whether targeting DDR proteins does indeed offer new therapeutic opportunities we 
utilised several complimentary strategies to try and determine the inherent ‘druggability’ of DDR 
proteins. Combined with SSL data and the careful analysis of individual DDR pathways, we have 
identified a range of tractable targets for each DDR pathway. 
 
DDR proteins with small molecule modulators.  Using the target annotation tools in canSAR55, based on 
data from ChEMBL56, we identified compounds with sub-micromolar activity and/or affinity for 55 of the 
~450 DDR targets including 46 drug-like, rule-of-five compliant compounds57 (Fig. 1 and details in 
Supplementary information S10 (Table)). Of these, 24 have compounds approved or under clinical 
evaluation. However, 30 targets are still in the discovery phase with no molecule yet advanced to 
clinical study but that potentially represent the next generation of DDR targets. Of these 30, 11 have 
orthologues involved in SSL relationships in yeast that indicate genetic backgrounds in which 
compounds might have clinical utility.  
 
Assessment of the druggability of DDR proteins. Using the canSAR55 knowledge-base we have used 
several methods to estimate the tractability of the DDR proteins themselves, as potential drug targets.  
We estimated DDR protein druggability based on the chemical properties and bioactivity of small 
molecules annotated in the ChEMBL56 database using a ligand-based assessment protocol55.  We 
identified 216 proteins incorporating domains where homologues had previously been tested for 
interaction with chemical matter, of which 107 (including ERCC4, XRCC5, FAN1, SMARCA2, DAXX 
and SMC4 - see Supplementary information S11 (table)), were predicted to be druggable.  
We also employed a structure based assessment method56, 58 that identifies cavities on the surface of a 
protein structure and assesses their likely druggability based on physiochemical parameters 
independent of the protein’s homology to known drug targets. The importance of the DDR is reflected in 
a high level of interest from structural biologists, with over half (246; 55%) of the DDR gene products 
having been structurally characterised to some degree. This set of proteins can further be expanded for 
druggability analysis by identifying structurally characterised close-homologues. 
Of the 291 proteins with experimental structures, or a closely homologous structure (greater than 50% 
sequence identity), 38% (175) are predicted to contain druggable binding sites using the DrugEBIlity
56 
algorithm, including PNKP, WRN, INO80, DCLRE1B, and PIF1 (see Supplementary information S12 
(table)).  Examining druggability by functional class confirms the expectation that enzymes are the most 
likely targets, with 72% considered druggable, although over half (53%) of scaffold proteins are also 
predicted to contain druggable binding sites.  
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Representation of the DDR network as a system of functional nodes connected by identified protein-
protein interactions, allows the application of network analysis techniques to predict key druggable 
intervention points. Using canSAR55, reliable network druggablity predictions could be made for 374 
proteins with sufficient experimentally-determined protein interactions. Of these, 105 were deemed 
druggable on the basis of network environment profiles similar to known cancer targets. There were 
significantly fewer candidates (p=0.03) identified than expected, probably reflecting the pathway 
structure of the DDR, which differs significantly to the signalling pathways more commonly drugged.  
Proteins occupying the most druggable network positions include RPA4, RAD51, DDB1, POLD3, 
SMARCA5, MEN1, and HUS1 (see Supplementary information S13(table)).  
 
Targeting proteins that regulate the DDR 
As well as assessing proteins within the DDR, we have also explored the set of proteins outside the 
‘core’ that are known to regulate DDR activity. 
Protein kinases regulating the DDR.  Many DDR processes are regulated by regulatory 
phosphorylation, so that protein kinases – a highly druggble protein class – are attractive targets for 
pharmacological modulation of DDR function. Considerable effort has already been expended on 
developing inhibitors of protein kinases that regulate DDR processes. These include the damage 
sensing PI3-kinase-like kinases ATM, ATR and PRKDC/DNA-PK, and the checkpoint kinases CHK1 
and CHK2 (Supplementary information S1(table)), as well as kinases specifically involved in mitosis 
and chromosome segregation such as AURB
59 and PLK160. Using the PhosphoSitePlus61 database we 
identified 82 kinases phosphorylating 141 DDR proteins (Supplementary information S14 (Table)). Of 
these, 18 kinases phosphorylate at least 10 DDR components or have DDR components as the 
majority of their known substrates. In addition to the DNA damage signalling kinases, the search 
identified CDK1, CDK2, GSK3β and CK2, which phosphorylate proteins in many cellular processes as 
well as DDR, so that specific modulation of the DDR would not be achievable by this route. A small 
number of more ‘specific’ phosphorylation sites dependant on kinases not normally associated with 
DDR were identified, however the biological significance of these remains to be determined. 
DDR regulation by ubiquitin.  Like phosphorylation, ubiquitination plays important roles in the regulation 
of DDR systems, both as a post-translational modification regulating complex assembly, and as a mark 
for degradation via the ubiquitin-proteasome system. Indeed a number of DDR proteins with clear 
cancer associations (e.g. BRCA1, FANCL) are themselves E3 ubiquitin ligases. Although the 
knowledge base for ubiquitination is far less well developed than that for phosphorylation, more than 
311 of the 448 proteins in our DDR set have been reported to be subject to ubiquitination of one sort or 
another, while 36 are also reported subject to modification by the ubiquitin-related SUMO protein 
(Supplementary information S15(table)).  This widespread involvement of ubiquitin (and SUMO) 
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modifications in DDR regulation, suggests that this system may offer opportunities for therapeutic 
intervention in cancer 62. 
The main druggable opportunity lies in the interaction between E3 ubiquitin ligases and their target 
proteins, which are often limited to a focal interaction of a peptide motif with a pocket or channel. One 
of the best examples of this type is the interaction of the E3 ligase Mdm2 with the DNA damage 
signalling protein TP53, whose loss or down-regulation is observed in the majority of cancers. Blocking 
the Mdm2-TP53 interaction prevents TP53 degradation and can restore apopotosis in tumours with 
wild-type TP53. A range of small molecule inhibitors of this interaction are being evaluated clinically 40. 
We identified 24 druggable E3 ligases within our core set of DDR proteins, and a further 16 that interact 
with DDR proteins and may warrant further investigation (Supplementary information S2 (methods) and 
S16 (table)).  
The enzymes that remove ubiquitin modifications of DDR proteins have also come under the spotlight 
as potential targets for small molecule therapeutics in cancer (reviewed in 63, 64). These 
deubiquitylating/deubiquitinating enzymes (DUBs) of which ~100 are identifiable in the human genome, 
hydrolyse the isopeptide bond linking the C-terminal glycine of ubiquitin with a lysine side chain on the 
target protein or another ubiquitin molecule. Usp1, which deubiquitylates PCNA and FANCD2, and 
Usp7, which deubiquitylates Mdm2, TP53 and a range of proteins involved in BER, NER and DNA 
damage checkpoint signalling, have been at the forefront of drug discovery for this class of enzymes 65, 
66.  There are 37 DUBs reported to interact with DDR proteins (Supplementary information S17 (table)) 
of which 23 are predicted to be druggable and of which 2 had reported inhibitors. siRNA knock-down of 
10 DUBs including USP20, UCLH5, and USP3 reduce the efficiency of DSB repair 67.63  Despite these 
interesting pre-clinical observations, the clear clinical settings for application of DUB inhibitors in cancer 
has yet to emerge. 
 
Identification of novel DDR targets 
Using a combination of methods, including druggability predictions, predicted and reported human SSL 
relationships and analysis of the DDR pathways, we have identified tractable targets for each of the 
DDR processes.  TABLE 2 shows examples of candidate targets for each of the major DDR processes, 
only five of which (CPF, NHEJ, BER, TM and P53) have current or candidate drug targets. Novel 
tractable targets lacking published chemical matter include XRCC5, MUS81 andPALB2.   
17 proteins were predicted to be druggable by all 3 prediction methods including LIG3 and FEN1.  
Inhibition of LIG3, a DNA ligase involved in BER, NER, and alternative NHEJ, could potentiate the 
activity of genotoxic agents
68.  FEN1, a DNA-flap endonuclease, is involved in BER and inhibiting it 
would be likely to be SSL with the HR defects observed in hereditary breast cancer.  A number of 
structurally diverse small molecule FEN1 inhibitors have been described 69-71, but all contain at least 
one significant structural alert and are not attractive start points for medicinal chemistry. Hits have been 
  14 
identified in a recently reported screen, but no details of the compounds have been disclosed72.  Other 
potentially druggable endo/exo-nuclease targets include DCLRE1B (Apollo), MUS81 and ERCC4 (see 
TABLE 2). 
Targets identified by at least two druggability methods and with reported chemical inhibitors include the 
BLM73 and WRN74 helicases. WRN is of interest because of its involvement with stalled replication 
forks, and its inhibition in an FA-defective background further perturbs the ICL response, leading to 
NHEJ activation74.  WRN inhibitors may have utility in the treatment of FA-deficient tumours in 
combination with DNA cross-linking agents. BLM inhibition sensitises tumour cells to conventional 
cancer therapies, such as camptothecin. 
Helicase targets lacking reported chemical matter include HELQ, HFM1, PIF1, INO80, SMARCA2 and 
SMARC4. Interestingly, SMARCA2, a chromatin remodelling gene with translocase and ATPase 
activities, predicted as druggable by all of our prediction methods, is SSL with the tumour suppressor 
SMARCA475 mutated in thyroid, ovary and lung cancers.  
Other enzymatic targets include the dual-function DNA end-processing enzyme PNKP, which restores 
the 5’-phosphate and 3’-hydroxyl moieties required for strand break joining in both SSB and NHEJ DSB 
repair. Blocking BER and NHEJ by inhibiting PNKP is expected to be lethal in cells defective in HR and 
could potentiate a range of genotoxic chemo- and radiotherapies  76 77. Interestingly PNKP knockdown 
elicited synthetic lethality in cells lacking PTEN – a commonly mutated tumour suppressor antagonising 
PI3-kinase signalling7, but the mechanism of this is not understood.  
Many DDR processes involve scaffold proteins that lack inherent catalytic or DNA-binding functions, but 
facilitate association of functional subunits into multiprotein complexes. Targeted disruption of the 
protein-protein interactions (PPI) the scaffold proteins mediate offers a novel approach to DDR 
inhibition DDR scaffolds where this could be effective include : TopBP1 – essential for assembly of 
replication initiation and DNA damage checkpoint systems; XRCC1 – essential for coordinating DNA 
SSBR short-patch repair downstream of PARP1; XRCC4 and XRCC6/KU70 – essential for assembling 
the NHEJ DSBR complex; Nbs1 (NBN) – essential for assembling the MRN DSB resection complex; 
and PALB2   - an essential HR component coupling BRCA2 to BRCA1 and Rad51
78.  Blocking the 
PALB2-BRCA2 interaction would inhibit HR and could have utility in cancers with aberrant SSBR. 
However, the interactions mediated by some of these scaffolds involve binding of phosphorylated 
motifs to basic binding sites in FHA or BRCT domains, so that development of cell-penetrant PPI 
competitive inhibitors of that type of interaction may prove problematic. 
 
Discussion  
For the foreseeable future, the main route to manipulation of an intracellular target will be via small 
molecules, typically acting by inhibition of a specific biochemical function of that protein. Many DDR 
proteins appear druggable in principle via this approach, and offer potential new targets for cancer drug 
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discovery. While there are fewer straightforward enzyme cofactor-binding sites than in the pathways on 
which most cancer drug discovery has hitherto focussed, the DDR is far from being dominated by 
intractability, and our analysis suggests that there are many eminently druggable targets to be 
explored. Novelty carries increased development risks compared to tried-and-tested target systems, but 
this can be mitigated by a willingness not just to discover and design clinical leads, but also to find 
small-molecule chemical tools that better define and validate potential targets, and help clarify the 
redundancy and interactions of the DDR target pathways. Such compounds need not be optimised for 
clinical use, but should be specific and potent enough to demonstrate target engagement, and 
sufficiently well tolerated to allow proof-of-principle experiments in cellular and animal models.   
Beyond any issues of druggability, there is the question of how readily DDR targets can be prosecuted 
using a cellular cancer drug discovery toolkit largely constructed and honed to address enzyme targets 
involved in post-translational modification or metabolic processes. For a protein kinase or phosphatase, 
methyltransferase, acetyl-transferase or deacetylase, the immediate pharmacological effect of a 
putative inhibitor can be readily observed using antibodies specific to the modified or unmodified state 
of the protein substrate of the target enzyme, or by gel-shift for ubiquitination / deubiqutination. For a 
metabolic enzyme target, the level of the direct small molecule product can usually be determined by 
mass spectrometry or by some specific secondary enzyme-coupled assay 
For many DDR targets however, especially those involved in DNA repair rather than damage signalling, 
the immediate end product is normal DNA, and the effects of pharmacological inhibition of a particular 
pathway are observed via readouts that may be some way downstream from the target protein itself. 
Thus, DDR drug discovery is currently dependent on relatively gross and usually semi-quantitative 
cellular assays such as the comet assay, which measures the levels of DNA double strand breaks; the 
alkaline comet assay, which measures the levels of double and single strand breaks; and 
immunological detection of γ-H2AX, a chromatin modification indicating the presence of unrepaired 
DNA breaks arising from a wide range of pathways. Clearly as DDR targets move to the fore in cancer 
drug discovery, considerable effort must be invested in the development of more specific assay 
techniques that approach the exquisite measurement of proximal effects that can be routinely achieved 
in drug discovery for cell signalling targets. 
Despite these challenges, our systematic analyses of the complex DDR system, utilising large scale 
genomic, structural and pharmacological knowledge, offers clear pathways to help focus future 
biological and drug discovery efforts, and offers glimpses of many largely unexplored therapeutic 
opportunities.  
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Figure Legends 
Figure 1:  DDR proteins with known small-molecule modulators. 
Histograms of small-molecule inhibitors that have been reported as tested in vitro or in vivo for efficacy 
against the DDR proteins indicated. Each bar shows the number of small molecules tested ; blue 
indicates compounds inactive at 1 micromolar, red indicates compounds showing activity, and green 
indicates active compounds that are compliant with Lipinski’s ‘rule of 5’ 57 for molecules that are likely to 
be of utility as drugs. Only proteins for which at least one active compound is recorded in the ChEMBL 
database have been included. The inserted pie chart indicates the type of protein domain targeted by 
the drugs. 
a|  Protein targets for which drugs have been licensed. 
b|  Protein targets where inhibitors have progressed to clinical trials. 
c|  Other proteins within the DDR for which reports of active small molecule modulators are present in 
the ChEMBL database. 
 
Figure 2 - A network view of the DDR 
A protein interaction network of the DDR proteins was generated using only experimentally derived 
protein-protein interactions extracted from the STRING database (see Supplementary information S2 
(methods) for details). DDR proteins connected to at least one other protein have been included in the 
network diagram.  Proteins have been coloured by membership of each individual DDR pathway. 
Nodes representing individual proteins are clustered on the basis of experimentally determined 
interactions using the Force Atlas algorithm implemented in Gephi 
79. This algorithm brings mutually 
interconnected proteins within the same pathway (e.g. NER, HR etc) into distinct clusters, while 
proteins in systems such as NHEJ and MMR, which have multiple interactions with other systems and 
pathways, are more diffusely distributed across the network. 
 
Figure 3 - Functional annotation of the DDR pathways 
a|  Pie-chart showing the distribution of the major protein functional classes to which each of the ~450 
DDR proteins have been assigned (see Supplementary information S2).  Enzymes and enzyme 
regulators, scaffold proteins, and transcription factors and regulators account for more than 75% of the 
DDR. Helicases constitute the largest class of enzyme in the DDR and represent an important class of 
target for which little chemical matter has yet been described. 
b| as a| but for 122 proteins for which a small molecule drug has been licensed for the treatment of 
cancer. Enzymatic targets are dominated by the protein kinases, which form only a small fraction of the 
targets in DDR. 
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c|  Enrichment of  protein coding mutations in DDR genes (see Supplementary 6 (table) and 
Supplementary 2 (methods)). AML, acute myeloid leukemia; OV, ovarian serous carcinoma; GBM, 
glioblastoma multiforme; KIRC, kidney renal clear cell carcinoma; BLCA, bladder urothelial carcinoma; 
COAD, colon adenocarcinoma; BRCA, breast invasive carcinoma; READ rectum adenocarcinoma; 
PRAD,  prostate adenocarcinoma; UCEC, uterine corpus endometrial carcinoma;  CESC, cervical 
squamous cell carcinoma; LUSC, lung squamous cell carcinoma; LUAD, lung adenocarcinoma. 
 
Figure 4:  Pathway-based disruption diagrams for individual cancers 
a| Polar plots of frequency of mutations of different DDR pathways in a range of cancers, based on data 
from The Cancer Genome Atlas. Radial extent indicates proportion of the patients analysed for each 
cancer type who had non-silent protein coding mutations in a component of the DDR pathway, arrayed 
circumferentially, that could disrupt the function of that pathway. Only genes mutated in at least two 
different patient samples were considered and mutation of multiple proteins in the same patient in the 
same pathway counted as a single pathway disruption. Numbers of patients in each study are 
indicated. Concentric circles indicate percentage (10, 30, 50, 70) of patients affected. See 
supplementary information S2(methods) for details and S7(table) for underlying data. 
b| Copy number variation in different DDR pathways. Inclusion criteria were as for a|; Concentric circles 
indicate percentage (10,30.50) of patients affected. Red indicates loss of gene copies – Blue indicates 
amplification. 
c| Expression level variation in different DDR pathways. Inclusion criteria were as for a|, with at least a 
two-fold change in level required; Concentric circles indicate percentage (10, 30, 50) of patients 
affected. Red indicates decreased expression  – Blue indicates increased expression. 
 
Figure 5:  Predicted human SSL within the DDR  
a| Network representation of predicted synthetic lethalities between human DDR pathways, based on 
experimentally determined negative genetic interactions between yeast orthologues of the components 
of each pathway or system. Network has a degree-sorted circular layout generated by Cytoscape
80.  
The size of each node, reflects the number of human proteins assigned to that system;  edge-widths 
are in proportion to the number of negative genetic interactions observed in the yeast data. 
b| Network representation of predicted synthetic lethalities between human DDR genes, based on 
experimentally determined negative genetic interactions between yeast orthologues of the components 
of each pathway or system. The network has a BioLayout generated by Cytoscape80.  Only genes with 
cancer-associated protein coding mutations that are SSL with TOP1, CHEK2, CHEK1 and CDK4 are 
displayed.  Targets with licensed inhibitors (TOP1) or those in clinical trials (CHEK1, CHEK2, CDK4) 
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are coloured yellow.  Genes with protein coding mutations are shown in green.  The darker the shade 
reflects the number of cancer-types where these genes are mutated in more than 1% of patients. 
 
Core DNA Repair Pathways 
Pathway Abbreviat
ion 
 
Type of Repair #genes 
involved 
Function 
Fanconi anemia 
pathway 
FA Double Strand 
Break Repair 
(DSBR) 
36 Responsible for repairing interstrand 
crosslinks{Kupfer, 2013 #143} (ICL). 
Homologous 
Recombination 
HR 52 The broken ends of a double strand 
break (DSB) are resected to allow 
invasion of the single strands into a 
homologous chromatid which 
functions as a template for accurate 
resynthesis of the damaged DNA81, 82.    
Non-
homologous 
end joining 
NHEJ 27 NHEJ ligates DSBs.  It does not 
require a template strand83. 
Base Excision 
Repair 
BER Single Strand 
Repair 
(SSR) 
42 Mono and bi-functional DNA 
glycosylases and nucleases 
excise damaged bases following 
spontaneous deamination, oxidation 
or alkylation to form 
Single Strand Breaks (SSBs).  SSBs 
also arise spontaneously from DNA 
sugar damage induced by reactive 
oxygen species.  
Polymerases are then used to mend 
these SSBs 
84. 
 
Direct Repair DR 3 A group of proteins that directly repair 
damaged DNA bases.  There are 
three common types of lesion 
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repaired O6-methylguanine, 1-
methyladenine and 3-
methylcytosine85. 
Mismatch 
Repair 
MMR 27 MMR corrects replication errors that 
cause the incorporation of the wrong 
nucleotide (a mismatch) and 
nucleotide insertions and deletions86. 
Nucleotide 
Excision Repair 
NER 66 NER removes helix-distorting addicts 
on DNA, for example those caused 
by UV radiation and tobacco smoke87.   
Trans Lesion 
Synthesis 
TLS 19 If damaged DNA bases or adducts 
are not repaired before replication 
has initiated, they may stall 
replication forks, contributing to 
genetic instability90.  Specialised 
translesion synthesis DNA 
poymerases are recruited to 
synthesise the DNA at these sites.   
Associated Pathways 
 
Pathway Abbreviation #genes 
involved 
Function 
Chromatin 
Remodelling 
CR 29 Chromatin remodelling enables 
dynamic access to packaged DNA88. 
Telomere 
Maintenance  
TM 28 Telomeres are the physical ends of 
chromosomes responsible for 
chromosome end protection. A 
capping structure prevents the 
exposed ends of DNA being 
“repaired” by DSBR and prevents 
otherwise exposed ends of different 
chromosomes from becoming fused 
together 
89. 
Checkpoint Factors CPF 54 The DDR requires integration with 
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TABLE 1:  This table identifies the major pathways in the DNA damage response and identifies the 
number of genes associated in each.  It is split into classical DNA repair pathways and the associated 
pathways.  Although members of the DNA repair pathways are as comprehensive as possible, for the 
associated pathways only the subset of genes most integrated with the DNA damage response have 
been included in our analysis.  Not all of the genes in our dataset have been assigned to one of these 
pathways, and genes may have membership of more than one pathway.  The full classification of every 
gene in the dataset is in Supplementary Information S3(table). 
  
other cell cycle processes via 
checkpoint signalling to allow time for 
repair to prevent DNA damage being 
made permanent by replication and 
mitosis91. 
Ubiquitin Response UR 29 The DDR involves a signalling 
transduction cascade utilizing many 
forms of post-translation modification 
of proteins, including phosphorylation 
and ubiquitination. Ubiquitination is 
used to target proteins for 
proteasomal degradation and is also 
involved in the regulation of protein 
function and mediating complex 
assemblies
92. 
P53 pathway  P53 9 Inclusion of genes in the P53 
apoptosis pathway that are involved 
in mediating DDR93 
Chromosome 
Segregation 
CS 16 HR is dependent on the sister 
chromatid and works in partnership 
with the chromosome cohesion 
machinery to ensure that defects are 
repaired before mitosis takes place. 
The chromatids are held together by 
cohesin until mitosis facilitating HR
94. 
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Pathway Current and Candidate 
Drug Targets 
Targets with 
Small molecule 
inhibitors 
<1UM 
Examples of ‘druggable’ 
biological targets 
 
CPF ATR, ATM, CHEK1, 
CHEK2, WEE1,  
CDK2, CDK4 
- TOPBP1 
NHEJ PRKDC (DNA-PK) - XRCC6 (KU70), XRCC5 
(KU80), PARP3, LIG4, PNKP 
BER PARP1, PARP2,  
APEX1 
POLB, FEN1,LIG1 PNKP,LIG3 
TM TERT TNKS DAXX, DCLRE1B(Apollo) 
P53 MDM2, TP53  MDM4, USP5 
NER - ERCC5 (XPG) ERCC4(XPF), XRCC1, POLD1  
MMR  - - MSH2, PMS2 
TLS - - POLQ, POLH, POLI, REV1, 
UBE2N, HLTF, PCNA, USP1 
HR - BRCA1, BLM, 
RAD51 
MRE11A, WRN, MUS81, 
BRCA2, PALB2 
FA - FANCF FANCM, USP1 
 
TABLE 2: Possible druggable targets for each of the major DDR pathways.  Further details of 
druggability assessments are available in Supplementary information S19 (table). 
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